| P2093 | author name string | Jing Yang | |
| | Yong Zhang | |
| | Xiaoyan Zhu | |
| | Yue Ming | |
| | Quanli Gao | |
| | Miaomiao Sun | |
| | Xiaomin Fu | |
| | Yalong Qi | |
| | Yiman Shang | |
| | Yonghao Yang | |
| P2860 | cites work | HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. | Q50761028 |
| | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 |
| | A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. | Q53347431 |
| | Tumour biology: herceptin acts as an anti-angiogenic cocktail. | Q53976093 |
| | Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio | Q82736634 |
| | Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays | Q83789922 |
| | A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study | Q84493586 |
| | Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer | Q95511307 |
| | Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer | Q37580326 |
| | Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer | Q37624508 |
| | Her-2/neu testing and therapy in gastroesophageal adenocarcinoma | Q37824265 |
| | HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. | Q38014506 |
| | Platelets effects on tumor growth | Q38229394 |
| | PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence | Q38649562 |
| | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 |
| | Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. | Q41596197 |
| | Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. | Q42373758 |
| | Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 |
| | Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways | Q43124366 |
| | Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients | Q44534842 |
| | The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer? | Q45217260 |
| | Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor | Q48369441 |
| | Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members | Q21195197 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Nitric oxide and peroxynitrite in health and disease | Q24645400 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 |
| | Global cancer statistics, 2012 | Q27860501 |
| | Cancer statistics, 2015 | Q27860576 |
| | Cancer-related inflammation | Q27860907 |
| | Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury | Q28252995 |
| | Nuclear factor-kappaB in cancer development and progression | Q29547879 |
| | Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation | Q33739796 |
| | Platelets guide the formation of early metastatic niches | Q34002250 |
| | Progress in human tumour immunology and immunotherapy | Q34253585 |
| | Biologic and therapeutic role of HER2 in cancer | Q34267775 |
| | The basic biology of HER2. | Q34346092 |
| | Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). | Q34446934 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | Epidemiology of gastric cancer in Japan | Q34559042 |
| | Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 |
| | Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy | Q34857119 |
| | Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis | Q35660696 |
| | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 |
| | A CXCL1 paracrine network links cancer chemoresistance and metastasis | Q36482032 |
| | Cytokine-induced killer cells promote antitumor immunity | Q36741617 |
| | Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer | Q37040591 |
| | Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. | Q37040624 |
| | Current approaches to gastric cancer in Korea. | Q37077836 |
| | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. | Q37109776 |
| | Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? | Q37131070 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade | Q37361541 |
| | Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer | Q37457430 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 6091-6100 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer | |
| P478 | volume | 11 | |